27th Apr 2016 09:00
LONDON (Alliance News) - Frontier IP Group PLC on Wednesday said its Ex Scientia Ltd portfolio company has entered into an agreement with German pharmaceutical company Evotec AG.
The pair will collaborate on developing bispecific small molecule immuno-oncology therapies, Frontier IP said.
"This is an ideal partnership to develop an innovative immuno-oncology portfolio where our focus is on delivering efficacious drug candidates to tackle the inherent challenges of the complex biology," said Andrew Hopkins, Ex Scientia's chief executive.
Shares in Frontier IP were up 11% to 31.04 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Frontier Ip